On the path toward meaningful treatments.

Our goal is to discover, develop and deliver innovative therapies that redefine the treatment of cancer and rare diseases. Currently, we are conducting clinical trials of our investigational drug candidates in PD-1 refractory metastatic melanoma and dermatomyositis. We are grateful to the participating patients, investigators and clinic staff who are helping us to advance this important research.

4.1_ContentImage_ClinicalPrograms_460px (1)

For more information about any of our clinical studies or study site locations, go to the U.S. FDA Clinical Trials Registry ,contact us directly at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

Current open trials

Metastatic Melanoma

A Phase 1/2 clinical trial of intratumoral IMO-2125 in combination with ipilimumab (a CTLA-4 antibody) or pembrolizumab (PD-1 blocking antibody) in patients with metastatic melanoma is underway and enrolling patients at five clinical locations within the United States. The trial is expected to enroll approximately 60-80 patients with the goal of determining the maximum tolerated dose, as well as the efficacy of IMO-2125 when administered intratumorally in combination with either ipilimumab or pembrolizumab.  For more information on this study and for a list of currently recruiting trial locations, go to the U.S. FDA Clinical Trial Registry Website ,contact Idera at clinicaltrials@iderapharma.com or visit Idera’s Clinical Trials Website.

Refractory Solid Tumors

A Phase 1b open-label trial designed to evaluate the safety and clinical activity of intratumoral IMO-2125 in patients with refractory solid tumors.  Additionally the study will evaluate multiple IMO-2125 dose levels with the objective of identifying best dose for future clinical trials.  For more information on this study and for a list of currently recruiting trial locations, go to the U.S. FDA Clinical Trial Registry Website, contact Idera at clinicaltrials@iderapharma.com or visit Idera Clinical Trials Website.

Dermatomyositis

A randomized, double-blind, placebo-controlled Phase 2 clinical trial of IMO-8400 in adult patients with dermatomyositis is currently enrolling patients with active skin disease who are unable to control their symptoms with current therapies. The trial will assess the compound’s safety, tolerability, and clinical activity when given to patients via weekly dosing for up to 24 weeks.  Eligibility criteria include a confirmed diagnosis of dermatomyositis, evidence of active skin and muscle disease, and a stable treatment regimen meeting pre-specified criteria prior to enrollment.

For more information on this study or study site locations, go to the U.S. FDA Clinical Trial Registry Site, contact Idera at clinicaltrials@iderapharma.com, or visit Idera’s Clinical Trials Website

Pioneer 2

  • Our Team

    Meet the team that’s dedicated to finding the next breakthrough for patients in need.